Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)

被引：0
|
作者：
Bender, Brendan C. [1 ]
Li, Chi-Chung [1 ]
Marchand, Mathilde [2 ]
Turner, David C. [1 ]
Li, Feifei [1 ]
Vadhavkar, Shweta [1 ]
Wang, Bei [1 ]
Deng, Rong [1 ]
Lu, James [1 ]
Jin, Jin [1 ]
Li, Chunze [1 ]
Yin, Shen [1 ]
Wei, Michael C. [1 ]
Chanu, Pascal [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Certara Inc, Marseille, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Bender, Brendan
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael
    Chanu, Pascal
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (06):
  • [2] Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Marshalek, Joseph P.
    Qing, Xin
    Dragan, Marcin
    Tomassetti, Sarah
    JOURNAL OF HEMATOLOGY, 2024, 13 (06) : 268 - 277
  • [3] Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
    Bartlett, Nancy L.
    Sehn, Laurie Helen
    Assouline, Sarit E.
    Bosch, Francesc
    Diefenbach, Catherine S. Magid
    Flinn, Ian
    Hong, Jungyong
    Kim, Wonseog S.
    Matasar, Matthew J.
    Nastoupil, Loretta J.
    Schuster, Stephen J.
    Shadman, Mazyar
    Yoon, Sung-Soo
    Bender, Brendan
    Kwan, Antonia
    Wang Cunlin
    Wei, Michael C.
    Yin, Shen
    Yousefi, Kasra
    Budde, L. Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.
    Schuster, Stephen J.
    Huw, Ling-Yuh
    Bolen, Christopher R.
    Assouline, Sarit E.
    Bartlett, Nancy L.
    Budde, L. Elizabeth
    Matasar, Matthew J.
    Koeppen, Hartmut
    Piccione, Emily C.
    Wilson, Deanna
    Wei, Michael C.
    Yin, Shen
    Penuel, Elicia M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Mosunetuzumab Retreatment is Effective and WellTolerated in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
    Cheah, Chan Yoon
    Nancy, Bartlett L.
    Sarit, Assouline E.
    Stephen, Schuster J.
    Kim, Won Seog
    Shadman, Mazyar
    Isufi, Iris
    Yin Shen
    Michelle, Doral Y.
    Sit, Jason
    Chen, Vivian
    Huang Huang
    Zhou Mingzhu
    Michael, Wei C.
    Budde, L. Elizabeth
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S45
  • [6] Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab
    Shahid, Zainab
    Okwali, Michelle
    Joseph, Ashlee
    Seo, Susan K.
    Lue, Jennifer Kimberly
    Boardman, Alexander P.
    Caron, Philip
    David, Kevin A.
    Epstein-Peterson, Zachary D.
    Ghione, Paola
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Johnson, William
    Kumar, Anita
    Moskowitz, Alison
    Noy, Ariela
    Owens, Colette
    Palomba, Maria Lia
    Stuver, Robert
    Torka, Pallawi
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Salles, Gilles
    Falchi, Lorenzo
    BLOOD, 2023, 142
  • [7] Maximum Tolerated Dose (MTD) and Safety Profile from Phase I Study of MT-3724 (CD20 targeted immunotoxin) in Relapsed/Refractory (R/R) Non-Hodgkin B-Cell Lymphoma (NHL)
    Fanale, Michelle A.
    Park, Steven I.
    Valacer, David J.
    Higgins, Jack
    Sloan, John Mark
    Younes, Anas
    Hamlin, Paul A.
    BLOOD, 2017, 130
  • [8] CD20 and CD19 expression loss in relapsed or refractory b-cell non-Hodgkin lymphoma: A retrospective cohort.
    Marshalek, Joseph Patrick
    Dragan, Marcin
    Tomassetti, Sarah
    LaBarbera, Katie
    Amaya, Andy
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
    Fanale, Michelle A.
    Hamlin, Paul A.
    Park, Steven I.
    Persky, Daniel Oscar
    Higgins, Jack P.
    Burnett, Christine
    Dabovic, Kristina
    Poma, Eric
    Sarapa, Nenad
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
12345